GALECTIN THERAPEUTICS INC

GALT

GALECTIN THERAPEUTICS INC

GALT

Insider Sentiment (TTM):

Last Purchase:2026-02-06Last Sale:2026-06-29Shares Purchased (TTM):6,500Shares Sold (TTM):743,133

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:13,594,761Shares Outstanding:65,782,000Institutional Ownership Pct.:20.67%

Earnings Market Reaction:

Filing Date:2026-08-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	13	14	18	12	14	7	15	27	26	24	26	20
Prepaid Expense And Other Assets Current	1	2	2	1	2	2	2	2	2	2	2	1
Assets Current	15	16	19	13	15	9	17	29	27	25	28	22
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	1
Property Plant And Equipment Net	-	-	0	-	-	-	0	-	-	-	0	-
Assets	15	16	20	13	16	10	17	29	28	26	28	22
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	3	3	5	6	7	6	3	4	4	6	3
Accrued Liabilities Current	4	4	5	5	5	7	8	12	11	9	9	8
Derivative Liabilities Current	-	-	0	4	0	0	0	0	-	-	0	-
Dividends Payable Current	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Current	152	7	8	136	11	111	35	25	15	13	16	11
Derivative Liabilities Noncurrent	0	3	4	0	2	0	0	2	2	2	1	1
Liabilities	152	146	146	136	133	122	121	121	110	97	88	73
Other Liabilities Noncurrent	-	-	-	-	-	-	0	0	0	0	0	0
Temporary Equity Carrying Amount Attributable To P…	2	2	2	2	2	2	2	2	2	2	2	2
Preferred Stock Value	0	0	0	0	0	1	1	1	1	1	1	1
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	308	305	304	301	299	297	296	295	294	292	292	291
Retained Earnings Accumulated Deficit	-447	-438	-433	-427	-419	-411	-402	-390	-378	-366	-354	-344
Stockholders Equity	-139	-132	-128	-125	-119	-114	-105	-94	-84	-73	-62	-53
Liabilities And Stockholders Equity	15	16	20	13	16	10	17	29	28	26	28	22
Temporary Equity Shares Authorized	0	0	0	0	0	0	0	0	0	0	0	0
Temporary Equity Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Temporary Equity Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Temporary Equity Aggregate Amount Of Redemption Re…	7,966	7,966	7,966	8,018	8,018	7,939	8	8	8	8	8	8
Temporary Equity Liquidation Preference	1,760	1,760	1,760	1,760	1,760	1,760	2	2	2	2	2	2
Preferred Stock Shares Authorized	2	2	2	2	2	2	2	2	2	2	2	2
Preferred Stock Shares Issued	1	1	1	1	1	1	1	1	1	1	1	1
Preferred Stock Shares Outstanding	1	1	1	1	1	1	1	1	1	1	1	1
Preferred Stock Liquidation Preference Value	1,185	1,210	1,210	1,210	1,210	1,235	1,235	1	1	1	1,235	1
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	150	150	150	150	150	150	150	150	150	150	150	150
Common Stock Shares Issued	66	66	65	64	64	63	63	62	62	62	62	62
Shares Outstanding	66	66	65	64	64	63	63	62	62	62	62	62

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	7.37%	107.83%	48.85%	-	-	-	-	-	-	-	-	-
2025	0.00%	65.15%	176.52%	22.34%	15.16%	54.52%	4.17%	-26.50%	-48.64%	-16.49%	-10.39%	1.43%
2024	-15.03%	-32.68%	-27.45%	9.33%	25.33%	11.11%	-25.45%	-57.82%	-54.55%	8.20%	4.92%	98.36%
2023	-	-	-	-	-	-	-2.56%	-12.82%	-9.74%	-	-	-
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	0.10	2.15	2.42	0.09	1.43	0.08	0.49	1.13	1.87	2.02	1.77	2.05
Quick Ratio	0.09	1.93	2.21	0.08	1.28	0.07	0.43	1.07	1.75	1.86	1.64	1.94
Working Capital	-136.96M	8.38M	11.41M	-123.72M	4.65M	-101.56M	-18.16M	3.41M	12.67M	12.83M	12.03M	11.09M
Leverage & Debt
Debt to Equity	-1.09	-1.11	-1.14	-1.09	-1.12	-1.07	-1.15	-1.29	-1.31	-1.33	-1.43	-1.39
Interest Coverage TTM	-2.02	-2.15	-2.74	-4.10	-5.01	-6.53	-7.66	-8.49	-9.91	-11.05	-13.64	-17.37
Debt Ratio	10.23	9.26	7.46	10.61	8.51	12.78	6.89	4.19	3.97	3.75	3.14	3.30
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.43	-0.40	-0.48	-0.58	-0.64	-0.71	-0.76	-0.67	-0.71	-0.66	-0.68	-0.76
Free Cash Flow Per Share TTM	-0.24	-0.30	-0.37	-0.48	-0.56	-0.59	-0.67	-0.54	-0.53	-0.55	-0.55	-0.59
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-30.46%	-41.45%	-34.16%	-10.13%	-9.00%	10.04%	14.56%	-8.74%	10.77%	1.36%	5.64%	28.15%
EPS Growth (1Y)	-33.02%	-43.75%	-35.81%	-12.83%	-10.74%	7.90%	10.61%	-12.51%	6.06%	-2.72%	4.29%	27.49%
Valuation Metrics
P/E TTM	-10.91	-6.94	-8.58	-7.30	-3.32	-1.71	-1.71	-4.13	-3.18	-3.61	-2.43	-2.52
P/B TTM	-2.21	-1.39	-2.08	-2.17	-1.13	-0.68	-0.77	-1.82	-1.68	-2.03	-1.61	-2.18
Market Cap	305.66M	183.53M	265.84M	272.23M	133.87M	77.11M	80.38M	171.26M	140.65M	148.12M	99.86M	114.63M
Enterprise Value	292.39M	169.42M	248.12M	260.70M	120.10M	69.68M	65.26M	144.20M	115.05M	124.57M	74.20M	94.27M
Calculated Values
Free Cash Flow TTM	-15.89M	-20.05M	-23.88M	-30.62M	-35.62M	-37.35M	-41.77M	-33.68M	-32.78M	-34.28M	-32.97M	-35.50M
Net Debt	-13.27M	-14.11M	-17.72M	-11.53M	-13.77M	-7.43M	-15.12M	-27.06M	-25.60M	-23.56M	-25.66M	-20.36M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-29Sale

Owner: Shlevin, Harold H.

Title: -

Shares: 22,268

Price/Share: $5.04

Value: $112,230.72

Shares Owned: 6,500

Relationship: Director

Ownership: Direct

2026-06-29Sale

Owner: Jamil, Khurram

Title: Chief Medical Officer

Shares: 47,467

Price/Share: $5.04

Value: $239,233.68

Shares Owned: -

Relationship: Officer

Ownership: Direct

2026-06-23Sale

Owner: Jamil, Khurram

Title: Chief Medical Officer

Shares: 7,557

Price/Share: $3.14

Value: $23,728.98

Shares Owned: -

Relationship: Officer

Ownership: Direct

2026-05-26Sale

Owner: Jamil, Khurram

Title: Chief Medical Officer

Shares: 568

Price/Share: $3.10

Value: $1,760.80

Shares Owned: -

Relationship: Officer

Ownership: Direct

2026-02-06Purchase

Owner: Eldred, Kary

Title: -

Shares: 300

Price/Share: $2.70

Value: $810.00

Shares Owned: 65,682

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-29	Shlevin, Harold H.	Director	-	Direct	Sale	22,268	5.04	$112,230.72	6,500	4
2026-06-29	Jamil, Khurram	Officer	Chief Medical Officer	Direct	Sale	47,467	5.04	$239,233.68	0	4
2026-06-23	Jamil, Khurram	Officer	Chief Medical Officer	Direct	Sale	7,557	3.14	$23,728.98	0	4
2026-05-26	Jamil, Khurram	Officer	Chief Medical Officer	Direct	Sale	568	3.10	$1,760.80	0	4
2026-02-06	Eldred, Kary	Director	-	Direct	Purchase	300	2.70	$810.00	65,682	4
2026-01-06	Lewis, Joel	Director,Officer	President and CEO	Direct	Sale	37,698	3.58	$134,958.84	832,592	4
2026-01-06	Jamil, Khurram	Officer	Chief Medical Officer	Direct	Sale	21,446	3.65	$78,277.90	0	4
2026-01-06	Callicutt, Jack W	Officer	Chief Financial Officer	Direct	Sale	20,354	3.67	$74,699.18	7,614	4
2025-12-31	Jamil, Khurram	Officer	Chief Medical Officer	Direct	Sale	8,125	4.07	$33,068.75	0	4
2025-12-23	Eldred, Kary	Director	-	Direct	Purchase	700	3.73	$2,611.00	65,382	4
2025-12-23	Freeman, Kevin D	Director	-	Direct	Purchase	5,500	3.55	$19,525.00	55,269	4/A
2025-12-17	Shlevin, Harold H.	Director	-	Direct	Sale	24,499	7.04	$172,472.96	6,500	4
2025-12-17	Lewis, Joel	Director,Officer	President and CEO	Direct	Sale	7,829	7.06	$55,272.74	832,592	4
2025-12-17	Jamil, Khurram	Officer	Chief Medical Officer	Direct	Sale	19,442	7.04	$136,871.68	0	4
2025-12-16	Czirr, James C, 10X Fund,…	TenPercentOwner	-	Direct	Sale	30,681	6.66	$204,335.46	5,614,457	4
2025-12-15	Shlevin, Harold H.	Director	-	Direct	Sale	8,417	6.30	$53,027.10	11,206	4
2025-12-09	Shlevin, Harold H.	Director	-	Direct	Sale	16,790	6.27	$105,273.30	11,206	4
2025-12-03	10X, Capital Management, …	TenPercentOwner	-	Direct	Sale	132,069	5.73	$756,755.37	5,670,138	4/A
2025-11-18	Callicutt, Jack W	Officer	Chief Financial Officer	Direct	Sale	46,310	6.22	$288,048.20	7,614	4
2025-11-18	Lewis, Joel	Director,Officer	President and CEO	Direct	Sale	6,783	6.15	$41,715.45	832,592	4
2025-11-13	Jamil, Khurram	Officer	Chief Medical Officer	Direct	Sale	121,117	5.47	$662,509.99	4,479	4
2025-11-11	10X, Capital Management, …	TenPercentOwner	-	Direct	Sale	40,000	5.25	$210,000.00	5,832,207	4
2025-11-10	Callicutt, Jack W	Officer	Chief Financial Officer	Direct	Sale	5,291	6.03	$31,904.73	7,614	4
2025-11-10	Lewis, Joel	Director,Officer	President and CEO	Direct	Sale	1,867	6.03	$11,258.01	832,592	4
2025-11-05	Lewis, Joel	Director,Officer	President and CEO	Direct	Sale	200	6.00	$1,200.00	832,592	4
2025-11-05	Callicutt, Jack W	Officer	Chief Financial Officer	Direct	Sale	600	6.00	$3,600.00	7,614	4
2025-11-04	Lewis, Joel	Director,Officer	President and CEO	Direct	Sale	14,420	6.07	$87,529.40	832,592	4
2025-11-04	Callicutt, Jack W	Officer	Chief Financial Officer	Direct	Sale	28,629	6.07	$173,778.03	7,614	4
2025-10-22	10X, Capital Management, …	TenPercentOwner	-	Direct	Sale	50,000	4.94	$247,000.00	5,872,207	4
2025-09-12	Callicutt, Jack W	Officer	Chief Financial Officer	Direct	Sale	8,706	6.44	$56,066.64	7,614	4
2025-09-12	Lewis, Joel	Director,Officer	President and CEO	Direct	Sale	14,000	6.36	$89,040.00	832,592	4
2025-07-21	Eldred, Kary	Director	-	Direct	Purchase	1,000	2.93	$2,930.00	64,682	4
2025-07-17	Freeman, Kevin D	Director	-	Direct	Purchase	5,000	2.90	$14,500.00	49,769	4
2024-12-30	Shlevin, Harold H.	Director	-	Direct	Purchase	6,500	1.16	$7,540.00	15,206	4
2024-12-24	Freeman, Kevin D	Director	-	Direct	Purchase	10,000	0.81	$8,100.00	44,769	4
2024-12-24	Zordani, Richard A. Jr.	Director	-	Direct	Purchase	10,000	0.82	$8,200.00	42,083	4
2024-12-24	Eldred, Kary	Director	-	Direct	Purchase	13,469	0.82	$11,044.58	63,682	4
2024-12-23	Lewis, Joel	Director,Officer	President and CEO	Direct	Sale	56,000	0.89	$49,840.00	897,012	4
2024-12-23	Callicutt, Jack W	Officer	Chief Financial Officer	Direct	Sale	40,000	0.89	$35,600.00	7,614	4
2024-12-23	Jamil, Khurram	Officer	Chief Medical Officer	Direct	Sale	13,654	0.88	$12,015.52	26,346	4
2024-10-23	Eldred, Kary	Director	-	Direct	Purchase	500	2.60	$1,300.00	50,213	4
2024-10-17	Freeman, Kevin D	Director	-	Direct	Purchase	1,300	2.64	$3,432.00	34,769	4
2024-10-16	Freeman, Kevin D	Director	-	Direct	Purchase	5,000	2.70	$13,500.00	33,469	4
2024-08-23	Zordani, Richard A. Jr.	Director	-	Direct	Purchase	1,759	2.30	$4,045.70	32,083	4
2024-07-22	Eldred, Kary	Director	-	Direct	Purchase	400	2.39	$956.00	49,713	4/A
2024-06-20	Freeman, Kevin D	Director	-	Direct	Purchase	2,500	2.38	$5,950.00	28,469	4
2024-04-30	Zordani, Richard A. Jr.	Director	-	Indirect	Purchase	1,000	3.52	$3,520.00	1,000	4
2024-04-24	Lewis, Joel	Director,Officer	President and CEO	Indirect	Purchase	1,000	3.39	$3,390.00	2,000	4
2024-04-23	10X, Fund, L.P., 10X Capi…	TenPercentOwner	-	Indirect	Sale	3,677	3.06	$11,251.62	5,922,207	5
2024-04-23	Czirr, James C	TenPercentOwner	-	Indirect	Sale	3,677	3.06	$11,251.62	5,922,207	4
2024-04-22	Freeman, Kevin D	Director	-	Direct	Purchase	2,500	2.98	$7,450.00	25,969	4
2024-01-16	Eldred, Kary	Director	-	Direct	Purchase	500	1.79	$895.00	49,313	4
2024-01-16	Eldred, Kary	Director	-	Direct	Purchase	400	2.39	$956.00	49,713	4
2023-07-19	Eldred, Kary	Director	-	Direct	Purchase	1,598	1.79	$2,860.42	48,813	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

20.67%

Inst. Shares: 13,594,761

Shares Outstanding: 65,782,000

2025-12-31

17.62%

Inst. Shares: 11,259,827

Shares Outstanding: 63,903,000

2025-09-30

15.04%

Inst. Shares: 9,653,528

Shares Outstanding: 64,205,000

2025-06-30

15.54%

Inst. Shares: 9,859,040

Shares Outstanding: 63,447,000

2025-03-31

14.92%

Inst. Shares: 9,432,554

Shares Outstanding: 63,204,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	13,594,761	65,782,000	20.67%
2025-12-31	11,259,827	63,903,000	17.62%
2025-09-30	9,653,528	64,205,000	15.04%
2025-06-30	9,859,040	63,447,000	15.54%
2025-03-31	9,432,554	63,204,000	14.92%
2024-12-31	9,684,549	62,309,000	15.54%
2024-09-30	9,068,401	62,278,000	14.56%
2024-06-30	8,745,418	62,233,000	14.05%
2024-03-31	7,349,354	61,976,000	11.86%
2023-12-31	6,904,466	60,159,000	11.48%
2023-09-30	8,726,760	59,704,000	14.62%
2023-06-30	6,951,837	59,582,000	11.67%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

GALECTIN THERAPEUTICS INC (GALT) — SEC Financial Statements & Analysis

GALECTIN THERAPEUTICS INC (GALT) is a pharmaceutical preparations company, incorporated in NV. GALECTIN THERAPEUTICS INC trades on Nasdaq as: GALT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), GALECTIN THERAPEUTICS INC reported a Debt-to-Equity ratio of -1.09x, a Price-to-Book (P/B) ratio of -2.21x (TTM), at a market cap of $305.66M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: -1.09x
P/B TTM: -2.21x
Market Cap: $305.66M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is GALECTIN THERAPEUTICS INC in?

GALECTIN THERAPEUTICS INC (GALT) operates in the Pharmaceutical Preparations industry.

What is GALT's market cap?

GALECTIN THERAPEUTICS INC (GALT) has a market capitalization of $305.66M as of 2026-06-30.

What exchange does GALT trade on?

GALECTIN THERAPEUTICS INC (GALT) trades on the Nasdaq.

Where is GALECTIN THERAPEUTICS INC incorporated?

GALECTIN THERAPEUTICS INC is incorporated in NV.